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Abstract Approximately 25% of all patients with stage II
colorectal cancer will experience recurrent disease and
subsequently die within 5 years. MicroRNA-21 (miR-21)
is upregulated in several cancer types and has been asso-
ciated with survival in colon cancer. In the present study
we developed a robust in situ hybridization assay using
high-afﬁnity Locked Nucleic Acid (LNA) probes that
speciﬁcally detect miR-21 in formalin-ﬁxed parafﬁn
embedded (FFPE) tissue samples. The expression of miR-
21 was analyzed by in situ hybridization on 130 stage II
colon and 67 stage II rectal cancer specimens. The miR-21
signal was revealed as a blue chromogenic reaction,
predominantly observed in ﬁbroblast-like cells located in
the stromal compartment of the tumors. The expression
levels were measured using image analysis. The miR-21
signal was determined as the total blue area (TB), or the
area fraction relative to the nuclear density (TBR) obtained
using a red nuclear stain. High TBR (and TB) estimates of
miR-21 expression correlated signiﬁcantly with shorter
disease-free survival (p = 0.004, HR = 1.28, 95% CI:
1.06–1.55) in the stage II colon cancer patient group,
whereas no signiﬁcant correlation with disease-free sur-
vival was observed in the stage II rectal cancer group. In
multivariate analysis both TB and TBR estimates were
independent of other clinical parameters (age, gender, total
leukocyte count, K-RAS mutational status and MSI). We
conclude that miR-21 is primarily a stromal microRNA,
which when measured by image analysis identiﬁes a sub-
group of stage II colon cancer patients with short disease-
free survival.
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Abbreviations
CC Colon cancer
RC Rectal cancer
CRC Colorectal cancer
DIG Digoxigenin
DFS Disease-free survival
ISH In situ hybridization
LCM Laser capture microdissection
LNA Locked nucleic acid
miRNA microRNA
NBT 4-Nitro-blue tetrazolium
BCIP 5-Brom-4-chloro-30-indolylphosphate
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Introduction
Colorectal cancer (CRC) is the third most frequent cancer
disease and the second most frequent cause of cancer
related mortality in the Western World. There are
approximately 600,000 new cases annually in these coun-
tries [1, 2]. In stage II CRC the tumor is conﬁned to the
bowel wall in contrast to stage III and IV, in which the
tumors have disseminated to local lymph nodes and distant
organs, respectively. Removal of primary stage II CRC is
therefore intended to be curative; however, 20–25% of all
stage II CRC patients will present with recurrent disease
and subsequent death from the disease within 5 years after
primary surgery. The majority of patients with stage II
CRC do not receive adjuvant treatment since at present
there is no evidence for a beneﬁcial effect of systemic
adjuvant treatment for this patient group as a whole [3].
MicroRNAs (miRNAs) constitute a group of 18–22
base-pair long non-coding RNAs. Some miRNA genes,
including miR-21, are transcribed as long non-coding
RNAs with polyadenylation [4]. miRNA biogenesis and
activity is only partially understood, but a generally
accepted sequence of steps is known as the ‘‘linear’’
canonical pathway [5].
miR-21 is consistently upregulated in a variety of cancer
tissues including colon [6, 7], esophagus [8], gastric [9],
lung [10], and breast cancer [11–15]. The human miR-21
gene is located on chromosome 17q23-1 overlapping with
the TMEM49 gene, a human homologue of rat Vacuole
Membrane Protein 1 VMP-1 [4, 16]. miR-21 encodes a
single hairpin and is regulated by its own promoter con-
taining binding sites for AP-1 and PU.1 transcription fac-
tors [16]. Several mRNAs have been identiﬁed as targets of
miR-21 mediated regulation including PDCD4 [17, 18],
SPRY1 and 2 [19, 20], NFI-B [16], RECK [21], and PTEN
[22–24].
To better characterize the molecular pathways regulated
by miR-21 in disease processes, determination of its cel-
lular origin is crucial. In situ hybridization (ISH) analysis
for miRNAs is a highly sensitive but technically chal-
lenging technology that is used to analyze miRNA locali-
zation and expression. The limited size of the miRNAs
requires highly speciﬁc detection reagents. In studies of
CRC tissues, ISH was utilized for cellular localization of
miR-21, but they present diverging results. Schetter et al.
[7] found miR-21 staining of an epithelial colon cancer
(CC) cell sub-population only, whereas Yamamichi et al.
[25] reported expression in both tumor cells and stromal
ﬁbroblasts. In a recent study that included CRC samples the
miR-21 ISH signal was also seen in both tumor and stromal
cells [26]. In this study we have employed high afﬁnity
LNA-modiﬁed DNA probes together with a series of
positive and negative control probes to show that miR-21 is
predominantly located in stromal ﬁbroblast-like cells
within the tumor. We also developed an image analysis-
based algorithm that allowed semi-quantitative assessment
of the ISH signal in the clinical samples and show a sig-
niﬁcant correlation between high miR-21 levels and short
disease-free survival in CC patients.
Materials and methods
Patients
This study included formalin-ﬁxed parafﬁn embedded
tumor specimens from 234 CRC patients [149 stage II
(Dukes B) CC and 85 stage II rectal cancer (RC) patients],
who were all part of the RANX05 study cohort [27]. The
original RANX05 study, approved according to the local
scientiﬁc-ethics committee for Københavns and Frederiksberg
Kommuner KF-200.2045/91, included 274 stage II CRC
patients in the Danish cohort. Not all departments provided
tissue samples, which resulted in 238 samples listed for the
current study. Four samples were not available resulting in
a total of 234 samples. Hematoxylin and eosin (H&E)
staining was performed on all 234 samples, and we noted
that seven samples (2 CC and 5 RC) did not contain cancer
tissue and these were therefore not processed for the ISH
analysis. The remaining 227 tumor specimens contained
both normal mucosa and tumor tissue. Of these an addi-
tional 30 samples (17 colon and 13 rectal tumors) had
either a small tumor area (\20 mm
2) or experienced sig-
niﬁcant tissue damage or prevalent staining artifacts after
ISH processing and were excluded in the statistical anal-
ysis. Patients within the RANX05 study underwent surgery
for CRC during 1991–1993 and were followed for at least
60 months. None of the CC patients received adjuvant
chemotherapy and none of the RC patients received radio-
or chemotherapy. Patients who were categorized as having
an event in the calculation of disease-free survival (DFS)
experienced local tumor recurrence in the form of either
local or distant metastasis, or death due to CRC, the latter
obtained from the Danish Causes of Death Registry.
Patients dying of all causes were considered as ‘‘death
events’’ and were included as such in the overall survival
(OS) analysis. Clinical data in addition to the follow-up
data, included gender, age, differentiation grade (high,
moderate or low), tumor type (adenocarcinomas, mucinous
or signet ring carcinoma) according to the WHO classiﬁ-
cation, total leukocyte count [28], microsatellite instability
28 Clin Exp Metastasis (2011) 28:27–38
123(MSI) [29], and K-RAS mutation status. Differentiation
grade, tumor type determination, MSI status and K-RAS
mutation status were obtained for CC, only.
LNA probes
DNA oligonucleotides with app. 30% Locked Nucleic Acid
(LNA) substitutions [30] for full length miR-21 (the
miRCURY
TM probe, predicted Tm * 82.7C, measured
Tm * 83.7C to miR-21 RNA target sequence): tcaa-
catcagtctgataagcta (Exiqon, Vedbaek, Denmark). Two
additional oligos for miR-21 were designed including a
17-mer at the 50-end (acatcagtctgataagc, predicted
Tm * 82C), and a 15-mer at the 30-end (tcaacatcagtctga,
predicted Tm * 81C). In addition, we prepared a 22-mer
probe containing three mis-matches (tcatcaacactctga-
taagcta, predicted Tm * 83C to complementary RNA
sequence, measured Tm * 61C to miR-21 RNA
sequence). A probe speciﬁc for U6 snRNA (cac-
gaatttgcgtgtcatcctt, predicted Tm * 84C, Exiqon) was
used as positive control, and a 22-mer scrambled probe
with a random sequence (gtgtaacacgtctatacgccca, predicted
Tm * 87C) having no known complementary sequence
target among human transcripts performing MegaBLAST
search at NCBI GenBank, was included as negative con-
trol. All LNA oligos were digoxigenin (DIG)-labeled at the
50- and 30-ends except the U6 probe, which was only 50-end
labeled, or if otherwise speciﬁed.
In situ hybridization
Six lm-thick parafﬁn sections were mounted on Super
frost ? glass slides and deparafﬁnized. The slides were
mounted onto ﬂow through slide chambers and placed in a
Tecan Freedom Evo automated hybridization instrument
(Tecan, Ma ¨nnedorf, Switzerland) in which the following
steps were performed: proteinase-K treatment 15 lg/ml at
37C for 8 min, pre-hybridization in Exiqon hybridization
buffer (Exiqon, Vedbæk, Denmark) at 62C for 15 min,
hybridization with 40 nM miR-21 probe, stringent washes
with 5 9 SSC, 1 9 SSC and 0.2 9 SSC buffers at 62C
over 33 min, DIG blocking reagent (Roche, Mannheim,
Germany) in maleic acid buffer containing 2% sheep serum
at 30C for 15 min, alkaline phosphatase-conjugated anti-
digoxigenin (diluted 1:500 in blocking reagent, Roche) at
30C for 30 min, enzymatic development using 4-nitro-
blue tetrazolium (NBT) and 5-brom-4-chloro-30-Indolyl-
phosphate (BCIP) substrate (Roche) forming dark-blue
NBT-formazan precipitate at 30C for 60 min, nuclear fast
red counterstain (Vector Laboratories, Burlingname, CA),
at 25C for 1 min. The slides were then dismantled in
water, dehydrated in alcohol solutions and mounted with
eukitt mounting medium (VWR, Herlev, Denmark). For
each patient, two slides were hybridized with the full
length miR-21 probe. To minimize day–day variations all
probes were pre-diluted in hybridization buffer in quanti-
ties determined for a single experiment. The same pro-
teinase-K stock was used through-out the experimental
period. The following steps were standardized in all steps
on different experimental days: tissue sectioning at 6 lm,
incubation times, incubation temperatures, pre-diluted
probes, antibody dilutions, proteinase-K batch. For probe
speciﬁcity analysis the full length miR-21 probe was
replaced with the 50-end probe, 30-end probe, 3-mismatch
probe, scrambled probe (all at 40 nM), or the probe for U6
snRNA (0.1 nM). For ﬂuorescent ISH, the sections were
processed as above, except that detection of the DIG-
labeled probes was done with peroxidase-conjugated sheep
anti-DIG (Roche) followed by TSA-FITC substrate
(Invitrogen, Taastrup, Denmark) according to manufac-
turer’s recommendations. Slides were coverslipped using
DAPI mounting media (Invitrogen).
Image analysis and quantiﬁcation
For image analysis we used the Visiopharm integrated
microscope and software module (Visiopharm, Hørsholm,
Denmark), comprising a Leica DM 6000B microscope
(Leica, Herlev, Denmark) equipped with an automated
stage and slide loader (Ludl, Hawthorne, USA) and an
Olympus DP72 CCD camera. Overview images of tissue
sections were captured using a 1.259 objective. The tumor
area (20–40 mm
2) was encircled on the overview images in
which 8–17 random image ﬁelds were collected using
systematic uniform random area sampling. The sample
images were captured with a 209 objective covering
0.29 mm
2 each. Exposure of sample images was strictly
controlled and locked at 6.993 ms with RGB (red–green–
blue) values at 170–180 in non-stained blank areas. Sample
images with tissue and staining artifacts were excluded. All
sample images included contained areas with evident
cancer cells and tumor stroma. Sample image exclusion
was done by an observer (BSN) unaware of the clinical
parameters. We employed supervised segmentation based
on Bayesian classiﬁcation using the Visiomorph software
tool. For miR-21 quantiﬁcation, the following histologi-
cally stained structures were differentiated: blue areas
(B) corresponding to the hybridization signal, red area (R)
corresponding to the red nuclear stain, purple areas (P)
corresponding to blue ISH signal overlaying nuclear red
stain. In addition, mucinous secretion stained with NFR
(mostly observed within normal mucosa and only sporad-
ically appearing in cancer areas) could be discriminated
and was considered as background signal. The following
parameters were obtained for each sample image: B, R, P,
total blue (TB = B ? P), total red (TR = R ? P), as well
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123as TBR = TB/TR. Minimal (less than 1%) mis-classiﬁca-
tion of the blue signal and no mis-classiﬁcation with the red
signal was observed when applying the pixel classiﬁer to
NFR stained sections with no NBT-formazan development
and to NBT-BCIP stained sections with no NFR counter
stain indicating that the classiﬁer efﬁciently discriminated
the blue NBT-formazan precipitate from the NFR stained
nuclei (data not shown). Three parameters obtained from
image analysis and reﬂecting relative miR-21 expression
levels were considered: (1) the stained area, (2) the staining
intensity and (3) the number of positive cells. Since the
stromal cells were often overlapping we did not pursue a
model based on numbers of positive cells. In our image
analysis set-up we evaluated a measure of ISH signal
intensity within the whole image ﬁeld. These intensity
values did not vary much and combining the intensity
parameter with area measures did not improve the corre-
lation of the area measure to survival. For determination of
the intra-assay variation, we captured random images
(n = 7) from six random slides three times. For these six
slides, the average CV was found to be 94% for TBR and
84% for the TB value, thus the same range as the inter-slide
variation that for all 197 cases were 67 and 71%, respec-
tively (see p. 14).
Laser capture microdissection and RT-qPCR
5 lm-thick parafﬁn sections were ﬁxed on PEN membrane
frame slides (Molecular Devices, Sunnyvale, CA) and
stained with Hematoxylin and Eosin. Tissue fractions
(50–200 9 10
3 lm
2) of normal adjacent mucosa, tumor
stroma, and cancer cells were isolated into separate Cap-
Sure
 Macro LCM Caps (Molecular Devices) using an
Arcturus Veritas Laser Capture Microdissection System
(Molecular Devices). RNA was puriﬁed using the FFPE
miRNeasy kit (Qiagen, Valencia, CA). RT-qPCR was
performed using the miRCURY LNA
TM
Universal RT
microRNA PCR system (Exiqon) on a Lightcycler-480
(Roche). Quantiﬁcation cycle (Cq) was calculated using the
2nd derivative method. Melting curve analysis was per-
formed to verify ampliﬁcation of single PCR products.
Determination of microsatellite instability (MSI)
MSI was determined in DNA puriﬁed from 10 lm-thick
parafﬁn sections by PCR for ﬁve markers as described [31].
Patients with MSI score 3–5 were considered MSI-positive.
K-RAS genotypin
K-RAS mutational status (wild type vs. mutation) was
determined on the puriﬁed DNA obtained for the MSI
analysis (above) using the Therascreen K-RAS mutation
qPCR kit (Qiagen/DxS, Manchester, UK) according to
manufacturer’s instructions. The qPCR analysis detects
the presence of 7 K-RAS mutations: Gly12Asp (GGT[
GAT), Gly12Ala (GGT[GCT), Gly12Val (GGT[GTT),
Gly12Ser (GGT[AGT), Gly12Arg (GGT[CGT),
Gly12Cys (GGT[TGT), and Gly13Asp (GGC[GAC).
The presence of one or more of these mutations categorized
the patient as positive in K-RAS mutational status.
Statistical analysis
All statistical calculations were performed using SAS
(version 9.1). The level of signiﬁcance was set to 5%.
Variance components for the estimation of intra-individual
variance and the inter-individual variance were done and
the results presented by the coefﬁcient of variation (CV)
and the intra-class correlation coefﬁcients (ICC). The
Wilcoxon rank sum test was used to test for differences in
levels between cases clinical parameters. DFS analysis was
done using the Cox proportional hazards model and deﬁned
as local recurrence, distant metastases or death attributable
to CRC (primary cause). Overall survival (OS) was deﬁned
as death due to any cause. Age and gender were included as
baseline covariates. All analyses were stratiﬁed by locali-
zation. The miR-21 values (TB or TBR) were analyzed as
continuous variables on the log scale (base 2). The esti-
mated HR values are therefore representing a 2-fold
increase in the miR-21 values. Model validation has been
done for the proportional hazards assumption and linearity
of the covariates. Kaplan–Meier estimates of DFS are
presented with patients grouped by the tertiles of the miR-
21 values with differences between strata tested using the
log-rank statistic. The assumption of linearity and the
proportional hazards assumption were assessed using
Schoenfeld and martingale residuals.
Results
Localization of miR-21 in CRC
For speciﬁc identiﬁcation of miR-21 in tissue sections using
ISH, we employed high-afﬁnity LNA-containing DNA
oligos labeled at both the 50- and 30-ends with DIG. Various
hybridization conditions, including tissue pre-digestion,
probe concentrations and hybridization temperature were
analyzed. Under optimized conditions (see material and
methods) we observed strong signal with the double-DIG-
labeledmiR-21probeinparallelwithlittleornobackground
stain, and no signal with the double-DIG-labeled scrambled
probe (Fig. 1a, c). Mix-incubating the miR-21 probe with a
2-fold excess of un-labeled probe during hybridization or
pre-incubatingtissuesectionswithun-labeledmiR-21probe
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123resultedinastrongreductionintheISHsignal(Fig. 1b).ISH
signal for snRNA U6 was observed in the nuclei of all cell
types (Fig. 1d). Two alternative LNA oligos speciﬁc for the
miR-21 sequence (17-mer and a 15-mer) showed an ISH
pattern identical to the 22-mer full-length probe, whereas a
22-mer miR-21 probe containing three mis-matches showed
no staining (Fig. 1e–h).
The miR-21 signal was predominantly observed in the
stromal compartment of the CRC (Figs. 1, 2a, b, 4). The
intensity varied from case to case and locally within the
lesions (Fig. 1a), although there was generally an abrupt
decrease of expression at the invasive front. Some cases,
approximately 20% (4/22), showed focal expression in
cancer cells as clusters within central tumor areas (Fig. 2b,
d) or in the tumor periphery (Fig. 2c). Only one case (out
of the total of 197 CRC cases) showed predominant miR-
21 expression in the cancer cells (data not shown), this
patient did not experience recurrent disease within the
follow-up period. Smooth muscle cells of muscularis ex-
terna often showed miR-21 expression where the cancer
Fig. 1 Speciﬁcity analysis of
miR-21 ISH signal in colon
cancer. Four serial tissue
sections were obtained from two
different colon cancers (a–d and
e–h). Tissue sections were
incubated with a full length
DIG-labeled LNA probe to
miR-21 (a), a mix of the DIG-
labeled LNA probe to miR-21
(40 nM) together with the un-
labeled version of the LNA
probe at 80 nM (b), DIG-
labeled LNA probe with a
scrambled sequence (c) and a
DIG-labeled LNA probe
(0.1 nM) speciﬁc for snRNA U6
(d). Intense miR-21 ISH signal
is seen with the miR-21 probe
(a, arrows), while mix-
incubating the DIG-labeled
miR-21 probe with miR-21
un-labeled oligo strongly
reduces the miR-21 ISH signal
(compare a with b). No signal is
seen with the DIG-labeled LNA
probe having a scrambled
sequence (c). The snRNA U6
ISH signal is exclusively
nuclear in all cells (d). Other
four serial sections were
incubated with double DIG-
labeled LNA probes as follows:
full length 22-mer miR-21
probe (e), a full length miR-21
probe with three mis-matches
(f), a 17-mer miR-21 probe (g),
and a 15-mer miR-21 probe (h).
The three miR-21 probes show
an identical hybridization
pattern, with intense signal in
stromal ﬁbroblast-like cells (e,
g, h, examples indicated by
arrows). Three mis-matches
placed at DNA positions
completely prevent
hybridization of the probe (f).
Bars: a–h:4 0lm
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smooth muscle under the normal mucosa was miR-21
negative (data not shown). We did not observe any obvious
differences in miR-21 expression pattern comparing CC
and RC. The miR-21 expression pattern was characterized
by intense expression in the tumor area in contrast to the
normal mucosa, where weakly stained spherical mononu-
clear cells were occasionally observed (Fig. 2f). Intense
miR-21 ISH signal was also observed in the stromal
compartment using ﬂuorescence detection (data not
shown). Comparative RT-qPCR was performed on laser
capture microdissected colon cancer samples. The levels of
miRNA-21 were normalized to the levels of miR-103 and
let-7a, which by genome-wide analysis were identiﬁed
among the most stably expressed miRNAs in these sam-
ples. The tumor stromal cells demonstrated 6-fold higher
levels (p\0.001) of miR-21 than the cancer cells or
normal colon tissue (Fig. 3). We measured an app 2-fold
increased expression (p\0.05) in the cancer cell popula-
tion compared to normal colon tissue. Although this may
be explained by minor contamination of miR-21 from
adjacent stromal cells, it may also reﬂect discrete miR-21
expression in cancer cells.
Quantiﬁcation of the miR-21 ISH signal
Using the optimized ISH conditions, we analyzed the 130
CC and 67 RC cases for the expression of miR-21. Auto-
mated ISH allowed uniform incubations across all samples
and was used to process two slides from each case for miR-
21 expression analysis. Since the expression of miR-21
varied considerably within tumors a total of 13 random
image ﬁelds (median = 13, range 9–33) placed within the
tumor area (Fig. 4a) were acquired per patient for sub-
sequent image analysis. Because the expression of miR-21
Fig. 2 Localization of miR-21 in colorectal cancers. Tissue sections
from colon (b, d, f) and rectal (a, c, e) cancer samples were incubated
with a full length DIG-labeled LNA probe to miR-21. Strong miR-21
signal is observed in the stromal compartment (St), predominantly in
ﬁbroblast-like cells (a, b, black arrows) in both colon (b) and rectal
(a) cancers. Occasional small clusters of cancer cells are seen within
central areas of colon and rectal cancers (b, d, white arrows) as well
as at the invasive front (c, arrows). Weak miR-21 ISH signal is
observed in the nearby smooth muscle cells of muscularis externa
(indicated by mu in e). In normal mucosa in proximity to the cancer, a
weak ISH signal is seen in a population of lymphocytic cells (f,
arrows) located in lamina propria (Lp). Bars: a, b, e:4 0lm, c, d, f:
20 lm
Fig. 3 RT-qPCR for miR-21 in microdissected colon cancer tissue
compartments. Areas with colon cancer cells, normal tissue, and
tumor stroma were microdissected using LCM. The expression of
miRNA-21 was measured by RT-qPCR in duplicate RT and duplicate
qPCR for each data point. The levels of miRNA-21 were normalized
to the levels of miR-103 and let-7a, which by genome-wide analysis
were identiﬁed among the most stably expressed miRNAs in these
samples. The level of expression in normal colon was set to one and
the shown error bars show the standard deviation between determi-
nations (* p\0.05 (n = 5, t-test), ** p\0.001 (n = 5, t-test)
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123varied according to the number (and density) of positive
cells we made the simple assumption that the area covered
by the blue ISH signal corresponded to the relative miR-21
expression level. Thus, based on a Bayesian pixel classiﬁer
we determined the area of the blue ISH signal, termed B
(Fig. 4b, c). We also determined the area of the nuclear red
stain (R), as well as the purple area (P) representing the
blue ISH signal overlapping with nuclear red (Fig. 4d, e).
The following area parameters were obtained: B, R, P, TB
(B ? P), TR (R ? P), and TBR (TB/TR), of which TB and
TBR were included in the statistical analyses. Both TB and
TBR values represent a relative miR-21 expression level,
of which TBR represents values normalized to the nuclear
density.
Focal expression of miR-21 throughout tumor areas
together with random positioning of image ﬁelds caused a
considerable variation within slides (125%). However, the
precision of the average measures was sufﬁciently high,
giving CV = 67% for TBR values and CV = 71% for TB
values within individuals, in comparison with the CVs
between individuals, which were 245 and 275%, respec-
tively. The calculated ICCs (the variation for individuals
versus the entire variation) were 84% for both TBR and TB
values.
The descriptive statistics for the miR-21 quantiﬁcations
in the CC and RC groups are shown in Table S1. The miR-
21 expression levels, measured as TB or TBR values, were
similar in the CC and RC patient groups.
Association of miR-21 to clinical characteristics
Comparison with other clinical parameters showed that the
male patient group had signiﬁcantly higher TBR values
than the females (Table 1). However, this difference was
Fig. 4 Image analysis for quantiﬁcation of miR-21 ISH signal and
Kaplan–Meier estimates of the miR-21 levels to DFS. Typical
example of a whole tissue section (a) with normal mucosa (N), tumor
area (T) and submucosa (S) after ISH for miR-21 and counterstaining
with nuclear red. The tumor area is encircled and random system-
atically placed image positions are indicated by squared frames (a).
The sample images are captured with a 209 objective (b), which are
processed with a supervised pixel classiﬁer separating the blue ISH
signal, the red counter stain, and the purple ISH signal overlaying the
nuclear red (c). The area within the frames situated in the lower left
corner of (b) and (c) are in enhanced in (d) and (e), respectively, to
show the conversion of the blue ISH signal (d) into green (e), purple
(d) into yellow (e) and red (d) into red (e) in the classiﬁed image.
Kaplan–Meier estimates of DFS probabilities for miR-21 ISH
expression levels measured as TBR values obtained for the 130
colon cancers grouped by their tertiles f. The upper tertile with
highest miR-21 levels (green), the middle tertile with intermediate
miR-21 levels (blue), and the lower tertile with lowest miR-21 levels
(orange). Using a cut-point separating the 35% patients with the
highest miR-21 levels (blue curve in g) from those with the lowest
(orange curve in g). The number of patients at risk at time 0, 24 and
48 months for each stratum is shown below the axis and the number
of events is shown to the left. P-values were obtained using log-rank
statistics. Bars. a: 250 lm, b–c:4 0lm, d–e:4lm
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other clinical parameters (age, grade, type, total leukocyte
count, MSI, K-RAS) revealed any correlation with miR-21
expression levels measured as TBR and TB values.
Association of miR-21 to disease-free and overall
survival
For the patient cohort, the median follow-up time was at
least 60 months and the number of relapses was 34 and 29,
the number of deaths 62 and 34 among the CC and RC
patients, respectively. The CC patients with high miR-21
expression levels (TBR, log2-transformed values) had sig-
niﬁcantly shorter DFS (HR = 1.28, 95% CI: 1.06–1.55,
p = 0.004) and a higher overall death rate (OS,
HR = 1.17, 95% CI: 1.02–1.34, p = 0.03). Kaplan–Meier
estimates of DFS probabilities for TBR are shown in
Fig. 4f, g and for the TB values shown in Fig. S1A. The
Kaplan–Meier estimates for TBR (Fig. 4f) and TB values
(Fig. S1A) are virtually identical. Considering DFS, the
33% patients with the highest miR-21 TBR-levels, 73%
(95% CI: 60–87%) were alive 2 years after surgery,
whereas the same rate was 98% (95% CI: 93–100) among
the patient tertile with the lowest miR-21 levels. For the
middle tertile this number was 86% (95% CI: 75–965). The
Kaplan–Meier estimate of the TBR-levels using the 65th
percentile as cut-point (corresponding to an expected
recurrence rate of 25% adding a 10% margin) is shown in
Fig. 4g, and results in a HR of 2.39 (95% CI: 1.22–4.69)
for the high-risk population.
Correlation between miR-21 levels and DFS or OS was
not observed in the RC group (DFS, HR = 0.96, 95% CI:
0.81–1.15, p = 0.67 and OS, HR = 0.97, 95% CI:
0.83–1.13, p = 0.71), Fig. S1B, S1C.
Multivariate analysis
Multivariate Cox regression analyses of the DFS data were
performed to compare the statistical power of the measured
miR-21 expression levels, TBR and TB, and their potential
correlations to gender, age and total leukocyte count. Both
TB and TBR values were found to be independent pre-
dictors of DFS in the CC patient group (p\0.05), Table 2.
Including the other clinical parameters (differentiation
Table 1 Correlation analyses of miR-21 expression levels measured
as TBR to available clinical parameters for the colorectal cancer
patients
Clinical
parameter
n Percentage miR-21 TBR P value
Gender
F 84 43 0.075 (0.002–1.614) 0.034
M 113 57 0.127 (0.002–2.110)
Localization
C 130 66 0.100 (0.003–1.619) 0.86
R 67 34 0.1158 (0.002–2.110)
Age range
\70 91 46 0.115 (0.002–2.110) 0.62
70–80 80 41 0.114 (0.002–1.104)
[80 26 13 0.076 (0.011–1.619)
Grade
a
– 18 14 0.065 (0.003–0.536) 0.46
1 4 3 0.252 (0.084–0.533)
2 101 78 0.116 (0.004–1.619)
2–3/3 7 5 0.104 (0.004–0.692)
Type
b
A 114 86 0.116 (0.004–1.619) 0.10
M 15 12 0.070 (0.003–0.284)
S 1 1 0.059
Total leukocyte
count
c
196 100 R = 0.09
e 0.21
J-RAS
d
WT 127 64 0.115 (0.004–2.110) 0.29
Mutation 60 30 0.104 (0.002–1.620)
MSI
d
0 147 74 0.108 (0.002–2.110) 0.85
1 39 20 0.104 (0.004–0.692)
a Differentiation grade, available for the 130 colon cancers cases only
b Tumor type available for the 130 colon cancers cases only. A ade-
nocarcinomas, M mucinous. carcinomas, S signet ring carcinomas
c data from one colon cancer was not available
d PCR data not available in 10 cases (K-RAS) and 11 cases (MSI)
e Spearman rank correlation coefﬁcient
Table 2 Multivariate Cox analysis on DFS related to miR-21
expression levels measured as TBR (A) and TB (B) combined with
other clinical parameters, gender, age and total leukocyte count
(TLC). The TLC value was not available for one colon cancer
AC C ( n = 129) RC (n = 67)
p value HR CI p value HR CI
TBR 0.017 1.261 1.042–1.528 0.7137 0.968 0.816–1.150
Gender 0.338 0.695 0.329–1.464 0.8501 0.929 0.433–1.994
Age 0.914 1.002 0.968–1.037 0.3115 1.018 0.984–1.053
TLC 0.982 1.000 0.998–1.002 0.8860 1.000 0.997–1.002
BC C ( n = 129) RC (n = 67)
p value HR CI p value HR CI
TB 0.012 1.285 1.057–1.562 0.0586 0.854 0.726–1.006
Gender 0.313 0.682 0.324–1.434 0.9858 0.993 0.465–2.120
Age 0.544 1.011 0.975–1.049 0.3034 1.019 0.983–1.055
TLC 0.975 1.000 0.998–1.002 0.9564 1.000 0.997–1.003
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123grade, tumor type, K-RAS and MSI) in a multivariate
model with TBR (CC) resulted in p = 0.66, p = 0.71,
p = 0.70, p = 0.16, respectively.
Discussion
In the present study we show that a high expression level of
miR-21 measured by quantitation of chromogenic ISH
signal is associated with short DFS and OS in stage II CC
patients. The relative miR-21 expression estimates were
found to be independent of other clinical parameters
including age, gender, K-RAS and MSI status. We found
an intense and well-deﬁned miR-21 ISH signal in the
stromal compartment of the tumors using three distinct
high afﬁnity antisense LNA probes against the mature
miRNA. This localization was supported by RT-qPCR
analysis of LCM tissue compartments identifying a 6-fold
higher miR-21 level in the stromal compartment compared
to that in the cancer cell compartments. The formation of
ISH signal was strongly reduced by mix-incubating excess
un-labeled probe with the DIG-labeled miR-21 probe on
the tissue sections. In addition, no speciﬁc ISH signal was
observed with two negative control DIG-labeled oligos,
one similar to the full-length miR-21 oligo but containing
three mis-matches and one with a scrambled sequence.
Based on these speciﬁcity tests, we conclude that the ISH
signal observed represented the presence of genuine miR-
21. Taken together, our ﬁndings suggest that miR-21
derived from the stromal cell population contributes to the
hostile malignant properties of the primary CCs.
The stromal miR-21 positive cells observed in the CRC
were generally ﬁbroblast-like in morphology. Cancer
associated ﬁbroblasts constitute a heterogeneous cell pop-
ulation with signiﬁcant growth-promoting impact on tumor
progression [32, 33]. Most cancer-associated ﬁbroblasts are
myo-differentiated so-called myoﬁbroblasts that may
derive from one or more local cell populations like peri-
cryptal myoﬁbroblasts, quiescent interstitial ﬁbroblasts,
smooth muscle cells, circulating ﬁbrocytes, and/or by epi-
thelial-to-mesenchymal transition (EMT) [34–36]. Fibro-
blasts may act on tumor cells through expression of growth
factors, such as TGF-b, and thereby contribute to the sur-
vival and proliferation of tumor cells [32]. In addition, a
number of extracellular proteases are expressed in myoﬁ-
broblasts, facilitating tissue remodeling and growth factor
activation during tumor growth, for example, well-estab-
lished prognostic cancer biomarkers like uPA and PAI-1 as
well as TIMP-1 and MMP-2 are primarily expressed in
cancer associated myoﬁbroblasts [37, 38]. Sempere et al.
[26] included CC samples in their study and also found
miR-21 signal in both tumor cells and tumor associated
ﬁbroblast using a double ﬂuorescence approach. A
prevalent expression of miR-21 in CRC stroma was not
reported by Schetter et al. [7] who found discrete ISH
signals in the tumor area and described the miR-21 positive
cells as tumor cells. Yamamichi et al. [25] used an FITC-
labeled LNA oligo and TSA-based ampliﬁcation and found
expression of miR-21 ISH signal primarily in cancer cells
but also reported stroma cell expression. The reason for
these discrepancies is likely explained by cross-reaction of
the oligo to ‘‘similar sequences’’ allowed under suboptimal
hybridization conditions. Another possible reason for the
discrepancy is linked to the different reagents employed to
detect the labeled LNA oligo. It should be noted that in the
latter two studies [7, 16] only the scrambled probe was
included to support the speciﬁcity of the ISH signal
observed.
For our study we developed a novel ISH procedure for
LNA-based miRNA ISH considering procedures described
by others [39–41], but suitable for an automated set-up
using a Genepaint instrument [42]. We recently established
a manual ISH procedure and conﬁrmed the expression
pattern for miR-21 as well as for a number of other miR-
NAs in various tissues [43]. For semiquantitative analysis,
we employed an unbiased image sampling and analysis
approach to replace the manual and more subjective scor-
ing of the histological expression intensities. Using image
analysis we obtained quantitative estimates of the ISH
signal for miR-21 (TB) as well as the area ratio to the
nuclear density (TBR). Both estimates showed that the high
levels correlated signiﬁcantly to short DFS in the CC
patient group of which the TBR values provided the best
correlation. Adjusting the ISH signal to the cell density
provided a lower inter slide variation and may therefore
explain the slightly better correlation obtained for TBR.
The precision of the TBR and TB estimates for each patient
was fairly high compared to the variation among individ-
uals. For both TBR and TB estimates, we obtained high
ICC values, 84% for both TBR and TB, conﬁrming that the
inter-individual variation was substantially larger than the
intra-individual variation and a good indication that the two
parameters could be signiﬁcant biomarkers.
The signiﬁcant correlation of miR-21 to DFS and OS
may prove useful for future development of tests to identify
stage II CC patients at risk of disease recurrence. In this
study we found that miR-21 correlation to CC DFS was
independent of other clinical parameters available for some
or all of the patients. Thus, none of the parameters avail-
able (including age, gender, total leukocyte count, K-RAS
or MSI) for the CC patient group (alone or in combination)
correlated with DFS or miR-21 ISH levels. A signiﬁcant
correlation between high miR-21 levels and poor survival
in CC patients has also been reported by Schetter et al. [7]
These authors isolated RNA from normal tissue and CC
tissue from 52 stage II patients and obtained cancer/normal
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123ratios of miR-21 by qPCR. Recently, Schetter et al. found
that combining the miR-21 levels with a mRNA expression
score for inﬂammation (Il-6, IL-8, IL10, IL-12a and
NOS2a) allowed an even better prognostication of high risk
CC patients [6]. This is an interesting observation, which in
addition to enforcing the prognostic value of miR-21, also
suggests that the molecular proﬁle of the inﬂammatory
response in CC better reﬂects the risk than the total leu-
kocyte count available in our patient cohort. Increased
miR-21 levels measured by either microarray or qPCR
have been shown to correlate with poor prognosis in sev-
eral other cancer types including NSCLC [10], breast
cancer [11, 12], and head-and-neck cancer [44, 45]. It has
been demonstrated that the cellular origin of miR-21 is also
partly stromal in breast [46] and lung cancers [43]. All
these data further demonstrate miR-21 as an inherent
cancer associated miRNA with a signiﬁcant impact on
tumor growth and dissemination.
Our quantitative measurements of the miR-21 ISH sig-
nal identiﬁed a signiﬁcant correlation to DFS in CC
patients but not in the RC group. This could be a result of
surgical intervention being different or due to different
molecular pathways for cancer invasion and dissemination
in the two parts of the intestines. The RC patients included
in the present study were all operated before the intro-
duction of the TME (Total Mesorectal Excision) opera-
tional procedure [47]. The TME practice is associated with
a signiﬁcantly longer DFS probably due to excision of
more malignant tissue and/or lymph nodes [48]. Thus, the
surgical procedure of the RC patients in this study is a
likely confounding parameter that may have prevented the
detection of relations between biological events (here miR-
21) and disease progression. It cannot be excluded, how-
ever, that also other molecular pathways being speciﬁc for
the RC could contribute to the observed lack of a signiﬁ-
cant association between miR-21 and DFS in the RC
patients.
The miR-21 promoter contains putative binding sites for
AP-1, Ets/PU.1, C/EBPa, NFI, SRF, p53, and STAT3 [16].
Activation of the ERK-MAP kinase pathway, induced for
example by TGF-b, leads to AP-1 activation and has been
found to be augmented by miR-21 in cardiac ﬁbroblasts
[19]. TGF-b is expressed at high levels in CRC and induces
ﬁbroblast activation and differentiation into myoﬁbroblasts
in model systems [49] as well as in CRC tissue [50] where
most ﬁbroblasts are myoﬁbroblasts. The mechanism(s) of
action of miR-21 in cancer ﬁbroblasts is not known. In
various settings, miR-21 has been reported to affect
expression of the transcription factor NF1-B in PMA-
stimulated HL60 cells [16], Spry1 in cardiac ﬁbroblasts
[19], the tumor suppressor PTEN in hepatocytes and car-
diac ﬁbroblasts [22, 23], and the tumor suppressor PDCD4
in a variety of cell lines [17, 51]. The identiﬁed mRNA
targets vary according to the particular cell line being
analyzed.
We have demonstrated that the prevalent expression of
miR-21 in the stromal compartment of CC patients is
correlated with short DFS and shorter OS. However, it
remains unsolved how the miR-21 positive stromal cells
contribute to the malignant characteristics of these tumors
and whether the sporadic miR-21 positive epithelial cancer
cells are also important. If the stromal cell population is
directing tumor progression, how do we then explain the
recurrent disease after tumor excision? Is the submucosa
already primed for promoting local re-growth or are
potential metastatic sites already primed for stimulating
growth of un-detected micro-metastases? In this context,
the miRNAs are truly playing the role as molecular regu-
lators critical to disease progression. Such central roles in
cancer have led miRNAs to be considered attractive novel
therapeutic cancer targets, both for inhibiting oncogenic
miRNAs or by re-introducing miRNAs lost in cancer [52].
To this end, recently it has been demonstrated that miR-21
is strongly upregulated in cardiac ﬁbroblasts in a murine
heart failure model and that silencing the ﬁbroblast-derived
miR-21 using miR-21 antagonists can prevent or even cure
the functional deterioration [19].
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